Hyaluran is a biomarker in patients without sepsis-related liver injury or not?

INTRODUCTION: The aim of the present study is to evaluate the value of hyaluran (HA) as a biomarker of sepsis in patients not showing sepsis-associated liver dysfunction and to investigate the relationship between HA level and disease severity
METHODS: Sepsis patients that had been followed-up between 2015 and 2016 in intensive care unit of Erciyes University Hospital were included in this prospective study. Sepsis was defined according to the 2013 Sepsis Survival Campaign Guidelines. The patients were classified as sepsis, severe sepsis, and septic shock. Blood samples were collected from the patients on the first and the third days to measure the HA level. A single blood sample was collected from each subject in the control group. The demographic characteristics, the duration of intensive care unit stay, and mortality data of the patient and the control groups were analyzed.
RESULTS: A total of 46 patients and 30 control subjects were evaluated. HA levels were found to be higher in the sepsis group than the others. HA was neither a predictor of the disease mortality, nor was it correlated with the inflammatory markers, C-reactive protein (CRP), and procalcitonin (PCT).

DISCUSSION AND CONCLUSION: HA is not a sepsis biomarker in the patients with sepsis who do not show sepsis-associated liver dysfunction.